Tag: Abzena

A first patient has been dosed in a Phase 1 clinical study (NCT06440005) with AGX101, a novel TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapy for the treatment of solid tumors. AGX101, which is being developed by privately held biotech startup Angiex, is based on a new, groundbreaking ADC technology platform with a unique mechanisms of action.

Abzena, a life sciences company providing a series of specific serviced for the development of antibody-drug conjugates, earlier this week announced the launch of...

Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...

Abzena, a the life sciences company providing proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, including antibody-drug conjugates...

Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...

Earlier today, Abzena, a life sciences group providing services and technologies to enable development and manufacture of biopharmaceutical products, announced that it had signed...

Cambridge (UK) based Antitope, a subsidiary of Abzena, has signed an agreement to  collaborate with Synthon Biopharmaceuticals, a global pharmaceutical company based in Nijmegen,...